Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

News Healthcare & Pharma General Updates

Date: 17th Jan, 2025 Source: European Medicines Agency (EMA) Country: European Union Original Source

Brief

"On March 10, 2024, the European Medicines Agency's safety committee, PRAC, initiated a review to assess the risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) associated with medicines containing semaglutide. This review was prompted by concerns raised in two observational studies suggesting an increased risk."

This content is restricted.

Highlights content goes here...

This content is restricted.

European Medicines Agency (EMA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

Brief

European Medicines Agency (EMA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

Brief

European Medicines Agency (EMA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.